Evidence map›Paper›PMID 41699628›Full record

ArticleChinese medicine2026

Artemisiae Argyi exosome-like nanovesicles alleviate ALF by reducing oxidative stress and inhibiting inflammation through the TLR4/NLRP3/Nrf2 axis.

Wenjie Zheng, Yue Su, Yan Tang, Kexin Yu, Runlin Lin, Yiyi Shan, Yuanyuan Wang, Louqin Fu, Jingjing Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenjie Zheng *Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Yue Su *Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Yan TangZhejiang Chinese Medical University, Hangzhou, 310053, China.
Kexin YuClinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310014, China.
Runlin LinClinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310014, China.
Yiyi ShanClinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310014, China.
Yuanyuan WangClinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310014, China.
Louqin FuClinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310014, China.
Jingjing LiClinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310014, China. lijingjing@hmc.edu.cn.

Funding

China Postdoctoral Science Foundation No. 2024M752890National Science Foundation for Young Scientists of China No.82102330
6 · The paper itself

Abstract

In recent years, plant-derived exosome-like nanovesicles (PELNVs) have attracted considerable research interest as emerging therapeutic adjuvants or delivery vehicles. This study aimed to develop exosome-like nanovesicles derived from Artemisia argyi (AELNVs) and evaluate their therapeutic potential in ameliorating LPS/D-GalN-induced acute liver failure (ALF) in mice. In our in vitro study, oral administration of AELNVs significantly ameliorates liver pathological damage, reduced systemic inflammatory cytokine levels, and improved survival in mice with ALF. We demonstrated that AELNVs inhibited the TLR4/NF-κB/NLRP3 axis and suppress hepatocyte apoptosis, while concurrently activating the Nrf2-CYP2A5 pathway to alleviate oxidative stress and hepatotoxicity. Analysis of hepatic chemokines revealed that AELNVs mitigated the hepatic immune response by suppressing the CCL5/7-CCR5 and CXCL9/10/11-CXCR3 chemokine axes. Furthermore, RNA-miRNA alignment analysis identified MIR2916 as a key mediator through which AELNVs modulated the TLR4 and its downstream signaling pathways. Collectively, these findings reveal the therapeutic potential of AELNVs as a nanotherapeutic agent for ALF.

Indexed as

ALFInflammatory responsesMicroRNAPELNVsTLR4/NF-κB/NLRP3

Identifiers

PMID41699628
PMCPMC12911172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.